HTA policies

A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.

Law 3563 creates a Neuquén health technology assessment agency. Guadalupe Montero explains how it will weigh safety, benefit, equity and budget impact.

The G-BA has found no proven added benefit for dupilumab in chronic spontaneous urticaria, compared with omalizumab plus second-generation H1 antihistamines.

The Dutch health institute Zorginstituut Nederland has concluded that a second cochlear implant for adults with severe hearing loss in both ears belongs in the basic health package. #SyenzaNews #MarketAccess

Australia's PBS strategic agreements with the medicines industry expire on 30 June 2027. At a 23 October webinar, the health department, GBMA and Medicines Australia explained what the deals cover, how patients can feed in, and where industry says they have fallen short on access. #SyenzaNews #MarketAccess #HTA #PBS #Australia

Insulin analogue cost-effectiveness studies for adults with type 1 diabetes mostly point the same way: the newer products usually come out ahead of human insulin. A new systematic review says that headline rests on thinner ground than it looks. The paper, by Shiwa Yaghoubi Bina, Steve Njokuocha and the T1D Economic Evidence Synthesis Group, has been accepted for Value in Health. The version available now is a pre-proof, so figures could still change at copyediting. The World Health Organization funded […]

Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.

France reimbursed 90% of drug costs in 2024, yet many patients still feel shortchanged. Maurice-Pierre Planel breaks down the numbers behind the paradox. #SyenzaNews #MarketAccess #PharmaPolicy

❓ How is Portugal’s approval of ublituximab reshaping access to multiple sclerosis therapies? The decision introduces new restrictions that could limit patient options and complicate market entry for innovative MS treatments. Explore the full implications for healthcare access and regulatory strategy. #SyenzaNews #pharmaceuticals #HealthcareInnovation #MarketAccess #healthcarepolicy

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.

How is Portugal expanding access to advanced prostate cancer therapies? The country has approved reimbursement for the niraparib-abiraterone combination, strengthening patient options in oncology and highlighting progress in pharmaceutical market access. Discover what this means for treatment innovation and healthcare policy. #SyenzaNews #oncology #MarketAccess

How can Health Technology Assessment reshape funding for social care? Our latest analysis explores strategic approaches to HTA-informed funding and the vital role of support networks in building sustainable, equitable social care systems. Read the full piece to see how these strategies are driving meaningful change. #SyenzaNews #HealthEconomics #HealthcareInnovation #costeffectiveness #innovation